Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective.
Keith CooperEmma MaundMarcia Tomie TakahashiJonathan ShepherdPublished in: PharmacoEconomics (2024)